X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SUN PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SUN PHARMA NOVARTIS/
SUN PHARMA
 
P/E (TTM) x 295.9 46.9 630.9% View Chart
P/BV x 25.2 3.8 666.0% View Chart
Dividend Yield % 1.4 0.6 238.2%  

Financials

 NOVARTIS   SUN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-17
SUN PHARMA
Mar-17
NOVARTIS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs855842 101.5%   
Low Rs666572 116.3%   
Sales per share (Unadj.) Rs219.0131.6 166.4%  
Earnings per share (Unadj.) Rs19.132.7 58.4%  
Cash flow per share (Unadj.) Rs20.338.0 53.4%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.30.5 265.8%  
Book value per share (Unadj.) Rs307.0152.7 201.0%  
Shares outstanding (eoy) m29.962,399.26 1.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.55.4 64.6%   
Avg P/E ratio x39.821.6 184.1%  
P/CF ratio (eoy) x37.518.6 201.1%  
Price / Book Value ratio x2.54.6 53.5%  
Dividend payout %52.410.7 489.2%   
Avg Mkt Cap Rs m22,7791,696,877 1.3%   
No. of employees `0000.717.5 3.8%   
Total wages/salary Rs m1,39349,023 2.8%   
Avg. sales/employee Rs Th9,736.218,028.3 54.0%   
Avg. wages/employee Rs Th2,066.82,798.8 73.8%   
Avg. net profit/employee Rs Th849.04,479.5 19.0%   
INCOME DATA
Net Sales Rs m6,562315,784 2.1%  
Other income Rs m7026,232 11.3%   
Total revenues Rs m7,264322,016 2.3%   
Gross profit Rs m259100,893 0.3%  
Depreciation Rs m3612,648 0.3%   
Interest Rs m73,998 0.2%   
Profit before tax Rs m91790,479 1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m34512,116 2.8%   
Profit after tax Rs m57278,462 0.7%  
Gross profit margin %3.931.9 12.3%  
Effective tax rate %37.613.4 281.0%   
Net profit margin %8.724.8 35.1%  
BALANCE SHEET DATA
Current assets Rs m9,731329,537 3.0%   
Current liabilities Rs m1,830178,870 1.0%   
Net working cap to sales %120.447.7 252.4%  
Current ratio x5.31.8 288.6%  
Inventory Days Days4979 61.6%  
Debtors Days Days2583 30.2%  
Net fixed assets Rs m57204,766 0.0%   
Share capital Rs m1412,399 5.9%   
"Free" reserves Rs m9,056363,997 2.5%   
Net worth Rs m9,196366,397 2.5%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m11,499614,102 1.9%  
Interest coverage x128.423.6 543.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 111.0%   
Return on assets %5.013.4 37.5%  
Return on equity %6.221.4 29.1%  
Return on capital %10.124.8 40.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12944,118 0.3%   
Fx outflow Rs m1,73424,484 7.1%   
Net fx Rs m-1,60519,634 -8.2%   
CASH FLOW
From Operations Rs m-38070,822 -0.5%  
From Investments Rs m4,208-42,216 -10.0%  
From Financial Activity Rs m-3,318-22,854 14.5%  
Net Cashflow Rs m5106,107 8.4%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.1 39.0%  
FIIs % 1.6 23.0 7.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.3 259.0%  
Shareholders   41,647 133,026 31.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   J.B.CHEMICALS  SUVEN LIFE  CADILA HEALTHCARE  TORRENT PHARMA  PANACEA BIOTECH  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 22, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - STRIDES SHASUN LTD COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS